Results from a new study, presented at the 33rd Annual Meeting of The European Bone & Joint Infection Society, showed complete wound healing in patients with chronic osteomyelitis treated with ...
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the launch of a new ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from BONESUPPORT HOLDING ...
* NEW PRECLINICAL DATA(1) HAS BEEN PUBLISHED THAT FURTHER SUPPORT BONESUPPORT'S AMBITION TO DEVELOP A COMBINATION PRODUCT OF COMPANY'S PLATFORM TECHNOLOGY CERAMENT® AND BISPHOSPHONATE, A ...
Swedish startup BoneSupport has raised $14 million to back the drug-eluting aspects of its synthetic bone substitute. Its injectable, antibiotic-eluting product Cerament G was CE marked in 2013 and is ...
BONESUPPORT AB, an emerging leader in innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced ...
BOSTON, May 21, 2019 /PRNewswire/ -- BONESUPPORT™ , an emerging leader in orthobiologics for the management of bone voids, is now the exclusive distributor of CERAMENT® in the United States. CERAMENT ...
BONESUPPORT HOLDING AB ((BOEUF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
LONDON – Bonesupport AB has raised $37 million in private equity and debt to develop a pipeline of products that use its injectable biomimetic scaffold Cerament to deliver drugs to the bone and to ...
Swedish startup BoneSupport raised $37 million in a round of equity and debt financing it says it will use to support its Cerament platform, which is a drug-eluting, synthetic bone substitute. The ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the launch of the next generation of the company’s breakthrough antibiotic-eluting bone graft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results